The IDeate-Lung01 trial showed a 48% confirmed response rate with Merck’s B7-H3 directed antibody-drug conjugate in previously treated extensive-stage small cell lung cancer, with durable benefit ...

Interim results from the ongoing Phase IV LOTUS trial showed that Daybue delivered sustained behavioral improvements and manageable gastrointestinal outcomes in Rett syndrome patients over one year.

In this week’s Applied Clinical Trials Brief, we recap three top stories: Novo Nordisk’s stepwise approach to AI adoption, ...

Results from the Phase III STRIDE-13 trial (NCT06177912) showed that Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) demonstrated robust immune responses in children and adolescents aged ...

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, ...

In this Q&A, Randa Wahid of Indero, and Lyn Mursalo, a freelance clinical research professional, share how sponsors and CROs ...

The FDA-approved therapy is now included in National Comprehensive Cancer Network clinical guidelines as a treatment option ...

The open-label, multicenter AVONELLE-X trial evaluated the long-term safety and tolerability of Vabysmo in 1,036 patients with nAMD who completed one of the two Phase III studies, TENAYA (NCT03823287) ...

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, outlines how the Phase III NIMBLE trial showed cemdisiran improved daily ...

The FDA has granted Fast Track Designation to Sanofi’s SAR402663, an investigational one-time intravitreal gene therapy for ...

In this episode of the Applied Clinical Trials Brief, Shipra Patel, global therapeutic area section head for endocrinology ...

Eli Lilly has shared positive results from the Phase III BRUIN CLL-313 clinical trial (NCT05023980) evaluating Jaypirca (pirtobrutinib) versus chemoimmunotherapy (bendamustine plus rituximab) in ...